Edition:
India

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

11.83USD
18 Apr 2019
Change (% chg)

$-0.08 (-0.67%)
Prev Close
$11.91
Open
$11.83
Day's High
$11.94
Day's Low
$11.37
Volume
320,540
Avg. Vol
240,885
52-wk High
$26.08
52-wk Low
$10.72

Latest Key Developments (Source: Significant Developments)

AMAG Pharmaceuticals Inc - Combining Its Women's And Maternal Health Sales Forces Into One Integrated Sales Team
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS INC - IT WAS COMBINING ITS WOMEN'S AND MATERNAL HEALTH SALES FORCES INTO ONE INTEGRATED SALES TEAM.AMAG PHARMACEUTICALS INC - COMPANY WILL REDUCE ITS OVERALL HEADCOUNT BY APPROXIMATELY 110 EMPLOYEES.AMAG PHARMACEUTICALS INC - WORKFORCE REDUCTION IS EXPECTED TO BE SUBSTANTIALLY COMPLETED IN Q1 OF 2019.AMAG PHARMACEUTICALS-EXPECTS TO RECORD RESTRUCTURING CHARGES, INCUR FUTURE CASH EXPENDITURES TOTALING ABOUT $6.0 MILLION IN CONNECTION WITH WORKFORCE REDUCTION.  Full Article

Slayback Pharma Launches Hydroxyprogesterone Caproate Injection, Generic Equivalent Of Makena Injection
Tuesday, 22 Jan 2019 

Jan 21 (Reuters) - Slayback Pharma LLC::SLAYBACK PHARMA ANNOUNCES LAUNCH OF HYDROXYPROGESTERONE CAPROATE INJECTION, USP 1,250 MG/ 5 ML IN A MULTI-DOSE VIAL, THE FIRST GENERIC EQUIVALENT OF MAKENA® INJECTION 1,250 MG/ 5 ML MULTI-DOSE VIAL.SLAYBACK PHARMA LLC SAYS MAKENA IS A REGISTERED TRADEMARK OF AMAG PHARMACEUTICALS.  Full Article

AMAG Pharmaceuticals Pays Off $475 Million Of Senior Secured Notes
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS PAYS OFF $475 MILLION OF SENIOR SECURED NOTES.AMAG PHARMACEUTICALS INC - REDEEMED $475 MILLION OF ITS OUTSTANDING 7.875% SENIOR NOTES, USING PROCEEDS FROM SALE OF CORD BLOOD REGISTRY.  Full Article

Palatin Technologies Receives FDA Acceptance For Review Of Bremelanotide NDA
Monday, 4 Jun 2018 

June 4 (Reuters) - Palatin Technologies Inc ::PALATIN TECHNOLOGIES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF BREMELANOTIDE NDA.PALATIN TECHNOLOGIES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF BREMELANOTIDE NDA.PALATIN TECHNOLOGIES INC - PDUFA GOAL DATE FOR COMPLETION OF FDA REVIEW OF BREMELANOTIDE NDA IS MARCH 23, 2019.PALATIN TECHNOLOGIES - FDA'S ACCEPTANCE OF NDA TRIGGERS $20 MILLION MILESTONE PAYMENT TO CO UNDER ITS LICENSE AGREEMENT WITH AMAG PHARMACEUTICALS.  Full Article

AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal
Friday, 23 Mar 2018 

March 23 (Reuters) - Amag Pharmaceuticals Inc ::AMAG PHARMACEUTICALS - ‍CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION​.AMAG PHARMACEUTICALS - ‍SETTLEMENT DISMISSES & RESOLVES PATENT LITIGATION RELATED TO CO'S FERAHEME, 30 MG/ML, 17 ML SINGLE DOSE VIALS FOR INTRAVENOUS USE​.AMAG PHARMACEUTICALS - ‍IF SANDOZ RECEIVES FDA APPROVAL BY A CERTAIN DATE, SANDOZ MAY LAUNCH GENERIC VERSION OF FERAHEME ON JULY 15, 2021, OR EARLIER​.AMAG PHARMACEUTICALS - ‍SANDOZ TO PAY SALES ROYALTY OF GENERIC VERSION OF FERAHEME TO AMAG UNTIL EXPIRATION OF LAST FERAHEME PATENT LISTED IN ORANGE BOOK​.  Full Article

AMAG Reports Q4 Earnings Of $0.10 Per Share
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Amag Pharmaceuticals Inc ::AMAG REPORTS 2017 FINANCIAL RESULTS AND COMPANY UPDATE.Q4 EARNINGS PER SHARE $0.10.TOTAL GAAP REVENUES FOR Q4 OF 2017 WERE $158.3 MILLION, COMPARED WITH $151.6 MILLION.NON-GAAP REVENUE TOTALED $159.7 MILLION IN Q4 OF 2017, UP FROM $153.0 MILLION.SAYS AFFIRMS FINANCIAL GUIDANCE FOR 2018.QUARTERLY TOTAL REVENUES $158.3 MILLION VERSUS $151.6 MILLION.  Full Article

AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector
Thursday, 15 Feb 2018 

Feb 14 (Reuters) - Amag Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN.AMAG PHARMACEUTICALS - EXPECTS TO FILE A NEW DRUG APPLICATION THIS QUARTER FOR A NEW CHEMICAL ENTITY (BREMELANOTIDE) ​.AMAG PHARMACEUTICALS INC - ‍EXPECTS SUBCUTANEOUS AUTO-INJECTOR TO BE AVAILABLE IN SECOND HALF OF MARCH​.AMAG PHARMACEUTICALS INC - WILL CONTINUE TO OFFER IM FORMULATION OF MAKENA IN BOTH SINGLE-DOSE AND MULTI-DOSE VIALS​.AMAG PHARMACEUTICALS INC - ‍MAKEN'S 7-YEAR ORPHAN DRUG EXCLUSIVITY EXPIRED EARLIER THIS MONTH​.AMAG PHARMACEUTICALS - ANNOUNCES FDA APPROVAL OF MAKENA (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR ‍​.  Full Article

AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE.SEES Q4 2017 REVENUE $156 MILLION TO $163 MILLION.SEES FY 2017 REVENUE $613 MILLION TO $620 MILLION.SEES FY 2017 REVENUE UP 15 PERCENT.SEES Q4 2017 REVENUE UP ABOUT 5 PERCENT.- ‍FOR Q4 OF 2017, AMAG EXPECTS AN OPERATING LOSS OF BETWEEN $6 MILLION AND $16 MILLION​.- ‍EXPECTS 2017 TOTAL GAAP REVENUE TO BE BETWEEN $607 MILLION AND $614 MILLION​.SEES ‍ 2017 OPERATING LOSS OF BETWEEN $292 MILLION AND $302 MILLION (DUE PRIMARILY TO A Q3 NON-CASH ACCOUNTING CHARGE)​.SEES ‍2018 TOTAL GAAP REVENUE $500 MILLION - $560 MILLION​.SEES ‍2018 GAAP OPERATING LOSS $147 MILLION - $117 MILLION​.Q4 REVENUE VIEW $161.1 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $616.0 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $504.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Palatin Technologies signs licensing agreement with Kwangdong Pharma
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Palatin Technologies :Palatin Technologies announces signing of licensing agreement with Kwangdong Pharmaceutical for Republic of Korea.A NDA anticipated to be filed with U.S. Food and Drug Administration in Q1 of calendar year 2018​.  Full Article

Amag Pharmaceuticals Q3 loss per share $4.31
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Amag Pharmaceuticals Inc :Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights.Q3 loss per share $4.31.Q3 earnings per share view $0.18 -- Thomson Reuters I/B/E/S.Q3 revenue $153.7 million versus I/B/E/S view $168.5 million.Amag Pharmaceuticals Inc - ‍co has updated 2017 Makena revenue guidance to between $385 million and $395 million​.  Full Article

BUZZ-U.S. STOCKS ON THE MOVE-Eventbrite, oil stocks, Big Lots, Exxon Mobil, Costco

* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were on pace for their fifth day of losses on Friday, after weak U.S. jobs data in February added to concerns over cooling global growth that was sparked by a sharp fall in China's exports and a prolonged slowdown in the eurozone. At 1:55 p.m. ET, the Dow Jones Industrial Average was down 0.56 perc